



September 11, 2017

## **pSivida to Present at Rodman & Renshaw Annual Global Investment Conference**

WATERTOWN, Mass., Sept. 11, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that Nancy Lurker, President and Chief Executive Officer, will be presenting at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, September 12, 2017 at 10:50 am (ET) at the Lotte New York Palace in New York, NY.

A live audio and/or webcast and subsequent archived replay of pSivida's presentations may be accessed via the Investors section of the Company's website under "Resources - Events & Presentations" at [www.psivida.com](http://www.psivida.com). The replay will be available for 90 days after the event.

### **About pSivida Corp.**

pSivida Corp. ([www.psivida.com](http://www.psivida.com)), headquartered in Watertown, MA, is a leader in the development of sustained release drug products for treating eye diseases. pSivida has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases. The most recent, ILUVIEN<sup>®</sup>, a micro-insert for diabetic macular edema, licensed to Alimera Sciences, is currently sold directly in the U.S. and three EU countries. Retisert<sup>®</sup>, an implant for posterior uveitis, is licensed to and sold by Bausch & Lomb. pSivida's lead product candidate, Durasert micro-insert for posterior segment uveitis, is being independently developed. Two pivotal Phase 3 studies with Durasert achieved their primary efficacy endpoint at six months of follow-up with statistical significance, and the Company plans to file an NDA by the end of calendar 2017. pSivida's pre-clinical development program is focused on using its core platform technology Durasert<sup>™</sup> to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis and other diseases. To learn more about pSivida, please visit [www.psivida.com](http://www.psivida.com) and connect on Twitter, LinkedIn, Facebook and Google+.

### **Contact:**

#### **EVC Group**

Michael Polyviou/Doug Sherk - Investors  
[mpolyviou@evcgroup.com](mailto:mpolyviou@evcgroup.com); [dsherk@evcgroup.com](mailto:dsherk@evcgroup.com)  
212.850.6020; 646-445-4800

Thomas Gibson - Media  
[tom@tomgibsoncommunications.com](mailto:tom@tomgibsoncommunications.com)  
201-476-0322

 Primary Logo

Source: pSivida Corp

News Provided by Acquire Media